All four categories of asthma, including acute onset of asthma symptoms, exercise-induced bronchospasm
and asthma exacerbation indicate the use of SABAs because these drugs have an onset of three to five minutes, and last up to four hours.
, postprocedural pain, and diarrhea were most common in 670 patients 1-24 months old and were similar between treatment and placebo groups.
Exercise-induced asthma (EIA) is a common disorder characterized by bronchospasm
resulting from moderate to vigorous exercise.
A long-acting [beta]-agonist, approved for maintenance treatment of bronchospasm
associated with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.
Food and Drug Administration (FDA) has approved Xopenex[R] brand levalbuterol HCI inhalation solution for the treatment or prevention of bronchospasm
in children 6 to 11 years old with reversible obstructive airway disease, such as asthma.
In children who are prone to bronchospasm
(the constricting of the smooth muscle surrounding the airways as in an asthma attack) the presence of the RSV virus makes their airways even more reactive.
Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm
About 80 percent of asthmatics are subject to exercise-induced bronchospasm
, which can cause coughing, chest tightness, wheezing, stomachache or headache within 15 minutes of exercise.
Food and Drug Administration (FDA) for the long-term, maintenance treatment of bronchospasm
associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm
in adults, adolescents and children six years of age and older with reversible obstructive airway disease, said Akorn.
Combivent inhalers are indicated for people with COPD, on a regular bronchodilator who continue to have evidence of bronchospasm
and who require a second bronchodilator.
The other concern about rapacuronium was that there were a number of reports of bronchospasm
from the initial clinical trials.